B2M: A Potential Drug Target for Various Diseases (G567)

Target Name: B2M

NCBI ID: G567

Content of Review Report on B2M Target / Biomarker

B2M

B2M: A Potential Drug Target for Various Diseases

Beta-2-microglobulin (B2M) is a protein that is expressed in various tissues and cells in the human body. It is a member of the integrin family and is involved in cell adhesion, migration, and invasion. B2M is also known as CD133, MG-CSF, and GLT-1.5.

B2M is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for drug development.

Structure and Function

B2M is a transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in cell adhesion and migration, while the transmembrane domain is responsible for the interaction between B2M and various signaling pathways. The intracellular domain is involved in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

B2M is involved in various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. B2M is a positive regulator of the TGF-β pathway and has been shown to promote the formation of microglobules, which are small clusters of interacting proteins that play a critical role in cellular signaling.

B2M is also involved in the regulation of the actinin cytoskeleton. It has been shown to interact with the protein F-actinin and to regulate the distribution of actinin in cells. This interaction between B2M and actinin has implications for the regulation of cellular movement and the maintenance of cell structure.

B2M is also involved in the regulation of cell signaling pathways that are important for the development and progression of cancer. It has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth, survival, and angiogenesis.

Drug Development

B2M is a potential drug target because of its involvement in various signaling pathways that are important for the development and progression of cancer. Its unique structure and function make it an attractive target for drug development.

One approach to drug development against B2M is to use small molecules that can inhibit its activity. Small molecules that have been shown to inhibit B2M activity include inhibitors of the TGF-β pathway, such as inhibitors of the protein SMAD4, which is a negative regulator of the TGF-β pathway.

Another approach to drug development against B2M is to use antibodies that can selectively target it. Antibodies that have been shown to selectively target B2M include monoclonal antibodies (MCABs) that recognize specific epitopes on B2M.

Another approach to drug development against B2M is to use gene editing techniques to modify its expression. This can be done by using CRISPR/Cas9 to introduce mutations into the B2M gene that alter its function.

Conclusion

B2M is a protein that is involved in various signaling pathways and is a potential drug target for cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for drug development. Small molecules, antibodies, and gene editing techniques are all being used to develop drugs against B2M. Further research is needed to fully understand the function of B2M and to develop effective treatments for various diseases.

Protein Name: Beta-2-microglobulin

Functions: Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation (PubMed:25356553)

The "B2M Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B2M comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets